« Additional results showed a pronounced difference in the molecular response (JAK2V617F burden) between the 2 treatment arms, with “striking superiority of ropeginterferon at month 60,” Gisslinger noted.
Specifically, the median JAK2V617F allele burden at year 5 was 8.5 in the ropeginterferon arm vs 44.4 in the control arm (P < .0001). Additionally, the percentage of patients with a JAK2V617F burden of less than 10% was 53% vs 12% in the investigative and control arms, respectively (P <.0001).
Approximately 69% of patients assigned to ropeginterferon vs 21.6% of those assigned to the control experienced a molecular response at 5 years according to ELN criteria (P <.0001) »